Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

Area of Science:

• Biochemistry
• Hematology
• Molecular Biology

Background:

• Activated coagulation factor VII (FVIIa) circulates in a zymogen-like conformation to prevent thrombosis.
• Tissue factor (TF) binding is essential for FVIIa's biological activity and initiating blood clotting.
• Current treatments for bleeding disorders, like hemophilia, face challenges, especially with inhibitory antibodies.

Purpose of the Study:

• To design and characterize potent mutants of FVIIa with enhanced catalytic activity.
• To investigate the mechanism of increased activity in FVIIa mutants.
• To explore the therapeutic potential of these FVIIa analogues for bleeding disorders.

Main Methods:

• Site-directed mutagenesis of FVIIa to replace residues involved in zymogenicity.
• Assays to measure TF-independent factor X activation rates.
• Studies on calcium dependence and protease domain N-terminus accessibility.
• Evaluation of substrate specificity and TF-dependent stimulation.

Main Results:

• FVIIa mutants exhibited up to 100-fold increased TF-independent factor X activation compared to wild-type.
• Mutant activity approached that of the FVIIa-soluble TF complex.
• Mutants retained substrate specificity and could be further stimulated by TF.
• Mechanistic insights were gained through calcium dependence and chemical modification studies.

Conclusions:

• Engineered FVIIa mutants possess significantly enhanced catalytic activity.
• These mutants offer a promising avenue for treating bleeding episodes, especially in hemophiliacs with inhibitors.
• The study provides insights into FVIIa activation mechanisms and allosteric regulation.